Table 3 Univariate analysis of treatment and tumor variables on progression-free survival and overall survival for all patients with metastatic GIST experiencing generalized progression after imatinib treatment at time of cytoreductive surgery

Duration of preoperative TKI

0.146

0.997

  ≤ 24 mo

Ref

Ref

  > 24 mo

0.429 (0.13–1.41)

0.99 (0.22–4.56)

Location of disease

0.537

0.061

 Liver only

Ref

Ref

 Peritoneum only

2.49 (0.45–13.68)

1.83 (0.33–10.08)

 Both

1.15 (0.35–3.78)

1.28 (0.96–3.25)

Metastatic mitotic index

0.164

0.514

  < 5/50 HPF

Ref

Ref

  ≥ 5/50 HPF

2.4 (0.66–8.78)

1.64 (0.37–7.35)

Number of metastases

0.430

0.611

  ≤ 5

Ref

Ref

  > 5

1.72 (0.43–6.92)

0.581 (0.07–4.85)

Extent of resection

 < 0.001

0.002

 R0/1

Ref

Ref

 R2

12.55 (2.28–69.07)

16.06 (1.68–153.81)